---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-016317"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:20:46.402830+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission

## Summary
- Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).
- Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.
- Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.
- Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.
- August 2024 equity offering raised net $30.9M; workforce reduced by over 20%.

## SEC filing metadata
- accession: 0000950103-24-016317
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/0000950103-24-016317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/dp220702_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-016317
- JSON: https://secwatch.observer/filing/0000950103-24-016317.json
- Plain text: https://secwatch.observer/filing/0000950103-24-016317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.